Niagen Bioscience, Inc.NAGEEarnings & Financial Report
Niagen Bioscience, formerly ChromaDex, is a bioscience сompany based in Los Angeles, California founded in 1999. The company operates in multiple sectors including reference standards, dietary supplements, and ingredient technology. Niagen Bioscience is publicly traded on the NASDAQ.
Revenue
$29.1M
Gross Profit
$18.2M
Operating Profit
$7.1M
Net Profit
$7.2M
Gross Margin
62.5%
Operating Margin
24.4%
Net Margin
24.6%
YoY Growth
37.4%
EPS
$0.10
Niagen Bioscience, Inc. Q4 FY2024 Financial Summary
Niagen Bioscience, Inc. reported revenue of $29.1M (up 37.4% YoY) for Q4 FY2024, with a net profit of $7.2M (up 6197.4% YoY) (24.6% margin). Cost of goods sold was $10.9M, operating expenses totaled $11.1M.
Key Financial Metrics
| Total Revenue | $29.1M |
|---|---|
| Net Profit | $7.2M |
| Gross Margin | 62.5% |
| Operating Margin | 24.4% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
Niagen Bioscience, Inc. Q4 FY2024 revenue of $29.1M breaks down across 3 segments, led by TRUNIAGEN Consumer Product at $22.7M (77.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| TRUNIAGEN Consumer Product | $22.7M | 77.8% |
| Ingredients Segment | $5.8M | 19.7% |
| Other | $722.0K | 2.5% |
Niagen Bioscience, Inc. Revenue by Segment — Quarterly Trend
Niagen Bioscience, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as TRUNIAGEN Consumer Product and Ingredients Segment) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| TRUNIAGEN Consumer Product | $27.5M | $26.0M | $22.7M | $21.5M |
| Ingredients Segment | $5.7M | $7.2M | — | $8.2M |
| Other | $694.0K | — | $1.0M | — |
Niagen Bioscience, Inc. Annual Revenue by Year
Niagen Bioscience, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $129.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $129.4M |
| 2024 | $99.6M |
| 2023 | $83.6M |
| 2022 | $72.0M |
Niagen Bioscience, Inc. Quarterly Revenue & Net Profit History
Niagen Bioscience, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $33.8M | +16.2% | $4.1M | 12.2% |
| Q3 FY2025 | $34.0M | +32.9% | $4.6M | 13.5% |
| Q2 FY2025 | $31.1M | +36.8% | $3.6M | 11.6% |
| Q1 FY2025 | $30.5M | +37.6% | $5.1M | 16.6% |
| Q4 FY2024 | $29.1M | +37.4% | $7.2M | 24.6% |
| Q3 FY2024 | $25.6M | +31.2% | $1.9M | 7.3% |
| Q2 FY2024 | $22.7M | +11.9% | $-15.0K | -0.1% |
| Q1 FY2024 | $22.2M | -1.8% | $-492.0K | -2.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.2M | $22.7M | $25.6M | $29.1M | $30.5M | $31.1M | $34.0M | $33.8M |
| YoY Growth | -1.8% | 11.9% | 31.2% | 37.4% | 37.6% | 36.8% | 32.9% | 16.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $54.1M | $54.0M | $56.5M | $68.3M | $81.3M | $91.5M | $98.1M | $106.4M |
| Liabilities | $25.1M | $23.3M | $22.2M | $22.2M | $26.0M | $27.3M | $27.5M | $29.9M |
| Equity | $29.0M | $30.7M | $34.4M | $46.1M | $55.3M | $64.2M | $70.7M | $76.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $295000 | $-264000 | $3.5M | $8.6M | $7.9M | $1.3M | $3.7M | $679000 |